Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SUPPRESSION OF VAGUS-MEDIATED PANCREATIC-POLYPEPTIDE RELEASE BY THE MU-OPIATE RECEPTOR AGONIST LOPERAMIDE IN MAN
Autore:
RIEPL RL; REICHARDT B; AUERNHAMMER CJ; BEIER G; SCHOPOHL J; STALLA G; LEHNERT P;
Indirizzi:
UNIV MUNICH,KLINIKUM INNENSTADT,MED KLIN,ZIEMSSENSTR 1 D-80336 MUNICHGERMANY UNIV MUNICH,KLINIKUM GROSSHADERN,MED KLIN 2 D-80336 MUNICH GERMANY MAX PLANCK INST PSYCHIAT,DEPT ENDOCRINOL,INST CLIN D-8000 MUNICH GERMANY
Titolo Testata:
British journal of clinical pharmacology
fascicolo: 3, volume: 42, anno: 1996,
pagine: 371 - 377
SICI:
0306-5251(1996)42:3<371:SOVPRB>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
AXONAL-TRANSPORT; BINDING-SITES; SECRETION; CHOLECYSTOKININ; NERVE; GASTRIN; PHASE;
Keywords:
ATROPINE; BETHANECHOL; CERULETIDE; CHOLINERGIC SYSTEM; HYPOGLYCEMIA; MODIFIED SHAM FEEDING; PANCREATIC POLYPEPTIDE; VAGUS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
33
Recensione:
Indirizzi per estratti:
Citazione:
R.L. Riepl et al., "SUPPRESSION OF VAGUS-MEDIATED PANCREATIC-POLYPEPTIDE RELEASE BY THE MU-OPIATE RECEPTOR AGONIST LOPERAMIDE IN MAN", British journal of clinical pharmacology, 42(3), 1996, pp. 371-377

Abstract

1 Morphine suppresses the release of pancreatic polypeptide, a hormone under vagal cholinergic control. The intention of the study was to detect whether the mu-opiate receptor agonist loperamide is also able to inhibit pancreatic polypeptide release, and to define its site of action. 2 In groups of healthy subjects (n = 6 each) stimulation of pancreatic polypeptide was assessed in five different tests: (i) insulin-hypoglycaemia; (ii) modified sham feeding; (iii) intravenous infusion of the cholecystokinin analogue ceruletide; (iv) injection of corticotropin releasing hormone; (v) infusion of the muscarinic acetylcholine agonist bethanechol. All tests were performed after oral application ofeither a placebo or loperamide (16 mg), tests (ii) and (iii) were repeated with loperamide in smaller doses (2 and 6 mg), with loperamide plus naloxone, with naloxone alone, and with infusion of atropine. Plasma concentrations of pancreatic polypeptide were measured radioimmunologically. 3 Release of pancreatic polypeptide in test (i) to (iv) was completely blocked by 16 mg loperamide, whereas bethanechol-stimulatedrelease (test 5) was not influenced. Tests (ii) and (iii) showed thatthe inhibition was dose-dependent and could be attenuated by naloxone. The inhibitory effect of loperamide was comparable with that of atropine. 4 We conclude that loperamide causes a dose-dependent inhibitionof pancreatic polypeptide release mediated by vagal-cholinergic pathways, but does not have an atropine-like peripheral action.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 04:31:35